These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evolving role of stem cell transplantation in multiple myeloma. Harousseau JL; Moreau P Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846 [TBL] [Abstract][Full Text] [Related]
3. Advances in biology and therapy of multiple myeloma. Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785 [TBL] [Abstract][Full Text] [Related]
4. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706 [TBL] [Abstract][Full Text] [Related]
10. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Palumbo A; Attal M; Roussel M Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441 [TBL] [Abstract][Full Text] [Related]
11. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation]. Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701 [TBL] [Abstract][Full Text] [Related]
12. Role of stem cell transplantation. Harousseau JL Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma. Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727 [TBL] [Abstract][Full Text] [Related]
14. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076 [TBL] [Abstract][Full Text] [Related]
15. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
16. Novel biologically based therapies for myeloma. Anderson KC Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280 [TBL] [Abstract][Full Text] [Related]